Study site and reference | Study design | Follow-up, months | Mean age, years (range) | Cancers detected/screened, (%) | Sensitivity (%) | Cancer yield from MRI alone (%) [95% CI]a | Biopsies recommended as a result of MRI, % | PPV of biopsies performed on basis of MRI, % | ||
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  | Mammography | MRI | Ultrasound |  |  |  |
Germany [19] | P | 12 | 39 (18–65) | 4.7 (9/192) | 33 (3/9) | 100 (9/9) | 33 (3/9) | 6/192 (3.1) [0.9–6.0] | 14/192 (7.3) | 64 |
Canada [20] | P | 36 | 47 (26–65) | 9.3 (22/236) | 36 (8/22) | 77 (17/22) | 33 (7/21) | 7/236 (3.0)d [1.7–7.1] | 37/236 (15.7) | 46 |
Italy [21] | P | 24 | 46 (25–77) | 7.6 (8/105) | 13 (1/8) | 100 (8/8) | 13 (1/8) | 7/105 (6.7) [2.7–13.3] | 9/105 (8.6) | 89 |
Netherlands [22] | P | 12 | 42 (22–68) | 2.8 (3/109) | 0 | 100 (3/3) | - | 3/109 (2.8) [0.6–7.8] | 5/109 (4.6) | 60 |
United States [23] | R | None | 50b (23–82) | 3.8 (14/367) | 0c | 100 (14/14) | - | 14/367 (3.8) [2.1–6.3] | 59/367 (15.8) | 24 |
Netherlands [24] | P | 33 | 40 (19–72) | 2.4 (45/1,909)e | 40 (18/45) | 71 (32/45) | - | 22/1,909 (1.2) [1.1–2.4] | 56/1,909 (2.9) | 57 |
International [25] | P | None | 45 (26–86) | 1.1 (4/367) | 25(1/4) | 100 (4/4) | - | 3/367 (0.8) [0.2–2.4] | 23/367 (6.3) | 17 |